美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

71.56

-0.7881-1.09%

成交量：212

成交額：1.51萬

市值：71.57萬

市盈率：- -

高：71.56

開：71.36

低：71.30

收：72.35

52周最高：85.03

52周最低：55.03

股本：1.00萬

流通股本：1.00萬

量比：0.50

換手率：2.12%

股息：2.08

股息率：2.90%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。

中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議

中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額

GLP-1為王、專利懸崖逼近、新賽道搶跑跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大

據英國金融時報報道英國製藥商阿斯利康一直在探索與美國競爭對手百時美施貴寶合併的交易合併後將打造全球最大的製藥集團之一市值

GSK上半年核心營業利潤增長管線優化同步推進

经济参考网

美股異動 | 醫藥板塊走強葛蘭素史克(GSK.US)績後大升逾7%

美股異動｜醫藥股板塊普漲，葛蘭素史克漲近7%，安進升逾5%，艾伯維公司漲近4%，輝瑞、默沙東升逾3%

老虎资讯综合

美股開盤 | 三大指數升跌不一，康寧跌超14%，葛蘭素史克升逾4%，可口可樂升逾3%

老虎资讯综合

葛蘭素史克首席執行官：媒體電話會議發言稱，我們認為公司現有營收與收益流規模充足，足以抵消艾滋病藥物專利失效帶來的損失。

葛蘭素史克首席執行官就劍橋投資表示，我們並未尋求英國政府支持。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/GSKH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":71.5619,"timestamp":1787601600000,"preClose":72.35,"halted":0,"volume":212,"delay":0,"changeRate":-0.01089288182446441,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盤前交易","change":-0.7881,"latestTime":"08-25 05:34:08 EDT","open":71.36,"high":71.5619,"low":71.3,"amount":15118,"amplitude":0.00362,"askPrice":113.78,"askSize":100,"bidPrice":28.78,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":71.5619,"nav":72.35762,"aum":723648.55762,"dividendRate":0.029,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":71.3,"preClose":71.5619,"latestTime":"16:10 EDT","volume":6,"amount":429.3714,"timestamp":1787602204676,"change":-0.2619,"changeRate":-0.00366,"amplitude":0},"volumeRatio":0.5035630290959906,"impliedVol":0.1195,"impliedVolPercentile":0.2},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5035630290959906,"shares":10001,"dividePrice":2.0753,"high":71.5619,"amplitude":0.00362,"preClose":72.35,"low":71.3,"week52Low":55.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":71.5619,"eps":0,"divideRate":0.029,"volume":212,"delay":0,"ttmEps":0,"open":71.36,"prevYearClose":68.2031,"prevWeekClose":72.35,"prevMonthClose":71.6488,"prevQuarterClose":73.8574,"fiveDayClose":69.8844,"twentyDayClose":72.7499,"sixtyDayClose":72.3943},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660493380","title":"GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660493380?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 22:23","pubTimestamp":1787062997,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSKH","LU1829250122.USD","GSK.UK","BK4532","BK4007","BK4588","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456776","title":"中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456776","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456776?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:49","pubTimestamp":1787021377,"startTime":"0","endTime":"0","summary":"【中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议】据中外制药官网消息，8月18日，中外制药宣布已与葛兰素史克签署独家许可协议，葛兰素史克将获得抗登革热病毒抗体药物“AID351”的全球独家开发、生产和商业化权利，并负责该药物的临床开发及生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844335660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844335660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4532","BK4588","BK1191","GSK","BK4585","BK4007","LU1829250122.USD","GSKH","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456160","title":"中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456160","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456160?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:38","pubTimestamp":1787020681,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4588","GSKH","BK4585","LU1829250122.USD","BK4007","GSK","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","LFSC","601881","APXH","SBIO","XLVI","BBP","BIOY","BK0276","BK1147","BK1564","GSKH","BK0188","IBB","06881","BK4585","PBE","BK4588","GDOC","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659945158","title":"葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659945158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659945158?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:58","pubTimestamp":1786615104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","GSKH","GSK","GSK.UK","BK4007","LU1829250122.USD","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","BIOY","BK0102","BK4588","GSKH","LFSC","GDOC","SBIO","BK4585","IBB","WRND","600721","PBE","BK0216","BBP","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","WRND","BIOY","SBIO","PBE","APXH","IBB","LFSC","BK4585","XLVI","BBP","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0216","IBB","XLVI","WRND","GSKH","BBP","BK0102","APXH","LFSC","GDOC","BIOY","PBE","SBIO","BK4585","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XLVI","BK1564","AGIX","GDOC","BK0188","GSKH","ARTY","LFSC","BK4585","APXH","BIOY","BK0028","IBB","600958","PBE","AIPO","BK4588","SBIO","03958","BK1147","CHAT","BK0276","QTOC","BK0012","WRND","BK0183","BBP","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931998","title":"數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931998?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:18","pubTimestamp":1786367928,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美国的市场份额修改发稿日期，补充百时美施贵宝的投资计划路透8月10日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。赛诺菲计划通过直接投资公司现有基地以及与其他国内制造商建立合作伙伴关系，扩大其在美国的生产能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T4470YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU1228905037.USD","GLAM","SG9999014898.SGD","LU1988902786.USD","LU0211327993.USD","LU1674673691.USD","LU2746668974.SGD","LU2896262040.SGD","LU1989772840.SGD","LU0210528500.USD","IE0004445015.USD","IE0001KFT4U8.USD","TMED","GSK.UK","LU0225283273.USD","LU2471134523.USD","LU1066051498.USD","LU2471134879.HKD","IE00BJLML261.HKD","LU0859254822.USD","BK4568","IE00BZ1G4Q59.USD","LU1670711123.USD","LU0345769631.USD","LU1670711040.USD","LU2462157665.USD","LU0868494708.USD","IE00BBT3K403.USD","LU2168564495.EUR","BK4592","LU2462591350.SGD","SG9999001176.SGD","LU0310800379.SGD","NVO","LU1829250122.USD","LU0162691827.USD","IE00BK4W5L77.USD","IXJ","LU0795875169.SGD","BK7067","BIB","LU2129689605.HKD","LU1116320737.USD","LU1127390331.HKD","LU1145028129.USD","PAWZ","LU0109394709.USD","SG9999015986.USD","FTXH","SG9999014880.SGD","IE0000B7K699.USD","ABBV","IE00BLSP4239.USD","LU2125154778.USD","LU0395794307.EUR","JDOC","LU1261432733.SGD","PJP","LU0323591593.USD","IE00BJT1NW94.SGD","LU1032466523.USD","LU0689626769.HKD","IE00B42XCP33.USD","LU1720051108.HKD","LU0097036916.USD","BK4581","LU2129689431.USD","LU2324357040.USD","LU1069347547.HKD","MEDI","IE00BFXG1179.USD","LU0058720904.USD","LLYZ","GSKH","LU0079474960.USD","NVOH","LU0211328371.USD","LU0289739343.SGD","LU1868836591.USD","LU0320765489.SGD","IE00BVYPNW00.USD","LU1623119135.USD","LU0072461881.USD","LU0345769128.USD","LU2211815571.USD","LU1923622614.USD","LU1868836757.USD","LU1914381329.SGD","LU0238689110.USD","IE00BK4W5M84.HKD","LU0174119429.USD","LU1064131342.USD","LU2108987350.USD","LU1267930490.SGD","04332","IE00B19Z3B42.SGD","BK7501","BK4583","LU0965509283.SGD","GB00BDT5M118.USD","LU1023059063.AUD","IE00BKPKM429.USD","LU2028103732.USD","LU0158827781.USD","LU2360032135.SGD","LU0683600562.USD","LU2756315664.SGD","IE00B4R5TH58.HKD","LU1868836914.USD","SGXZ81514606.USD","LU0306807586.USD","LU2491049909.HKD","IE00BLSP4452.SGD","LU1894683348.USD","SGXZ31699556.SGD","SG9999014575.USD","LU2111349929.HKD","LU1917777945.USD","IE00BFSS8Q28.SGD","LU0320765646.SGD","LU2089284900.SGD","LU1057294990.SGD","LU0237698245.USD","LU2433249047.HKD","AMGN","LU2347655073.USD","LLYX","LU1935042991.SGD","IE00BVYPNV92.GBP","LU1074936037.SGD","LU1116320901.HKD","TRUH","IE000BZT7R73.USD","SG9999015978.USD","LU0053666078.USD","LU0820562030.AUD","LU0234570918.USD","LU0354030438.USD","LU0943347566.SGD","LU2237443465.HKD","LU0964807845.USD","LU2125909247.SGD","LU1059921491.USD","LU0354030511.USD","LU1244550494.USD","LU0208291251.USD","LU2237443549.SGD","LU0477156953.USD","SG9999014906.USD","IE00BKDWB100.SGD","IE0034235303.USD","BK4532","LU1035773651.USD","LU2106854487.HKD","LU2430703178.SGD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU2552382132.HKD","LU2505996509.AUD","LU0133085943.USD","IE000MB6IJN5.SGD","IE00BDGV0183.EUR","LU1670627923.USD","SG9999001176.USD","AZNH","LU0316494557.USD","IE00B2B36J28.USD","LU0210536198.USD","LU0471298694.HKD","LU1979441026.SGD","LU1670628061.USD","LU2242646821.SGD","SG9999014567.USD","AZN","LU1548497426.USD","LU1929549753.HKD","LU1629891620.HKD","RXL","IE000M9KFDE8.USD","LU0225284248.USD","IE00BWXC8680.SGD","BK4585","LU1571399168.USD","IE0005OL40V9.USD","LU1814569148.SGD","CSL.AU","LU1699723380.USD","LU2417539215.USD","LU0266013472.USD","IE00B1BXHZ80.USD","LU1868837300.USD","LU0949170772.SGD","LU1043141123.HKD","IHE","LU0820561909.HKD","LU0708995401.HKD","LU2168564149.EUR","LU2168563687.JPY","VHT","GSK","LU0985481810.HKD","IE00BJJMRY28.SGD","THNR","LU2264538146.SGD","LU1496350502.SGD","WDNA","BIIB","LU2461242641.AUD","ELIL","IBBQ","SG9999002232.USD","LU2360106947.USD","LU2361044865.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0432979614.USD","IE00B775H168.HKD","LU0203202063.USD","LU0353189763.USD","LU1778281490.HKD","LU1974910355.USD","LU0061475181.USD","LU1989771016.USD","LU0553294199.USD","LU2357627491.SGD","IE00BKVL7J92.USD","ILDR","LU2265009873.SGD","LU1280957306.USD","LU1221951129.SGD","LU2063271972.USD","SG9999015952.SGD","LU1221951046.USD","LU1003077747.HKD","IE00B19Z9P08.USD","LU1232071149.USD","LU0786609619.USD","LU0320765059.SGD","LU0672654240.SGD","LU2750360997.AUD","LU0158827948.USD","IBB","SG9999017495.SGD","LU0006306889.USD","LU0942090050.USD","LU1121112475.USD","MHIP","SG9999014542.SGD","LU0321505439.SGD","LU0234572021.USD","LU1244550221.USD","LU0114720955.EUR","LU0472753341.HKD","LU2430703095.HKD","SGXZ99366536.SGD","LU0648001328.SGD","LU0417517546.SGD","LU2237443978.SGD","BBH","LU0823434583.USD","BK4578","LU0738911758.USD","LU2087621335.USD","IE00BN8TJ469.HKD","IE00B1XK9C88.USD","LU0265550359.USD","LU2487616109.SGD","IE00BN29S564.USD","LLY","LU0640476718.USD","LU1267930730.SGD","LU0353189680.USD","LU0426412945.USD","LU0070302665.USD","BK4007","LU2357305700.SGD","LU1291159041.SGD","GILD","LU1868837136.USD","LU1201861249.SGD","SG9999001440.SGD","LU1732800096.USD","LU1712237335.SGD","LU0823434740.USD","LU2403377893.USD","BK4533","LU0198837287.USD","LU1670710588.SGD","LU1839511570.USD","LU1674673428.USD","LU1718418525.SGD","LU2596442595.SGD","IE00B4JS1V06.HKD","LU0203201768.USD","LU2089984988.USD","LU2430703251.USD","IYH","LU0820561818.USD","LU2491050154.USD","LU1323610961.USD","SG9999018857.SGD","LU2552382215.SGD","IE00BGHQF631.EUR","LU0096364046.USD","IE00B894F039.SGD","LU0289961442.SGD","LU0792757196.USD","LU2023250330.USD","BK4504","LU0310799852.SGD","LU2750360641.GBP","IE000F7OJYX1.SGD","SG9999002224.SGD","ELIS","LU0256863811.USD","LU0098860793.USD","LU0795875086.SGD","IE00B19Z3581.USD","LU2168564222.USD","LU0661504455.SGD","SG9999015341.SGD","LU2237438978.USD","LU0057025933.USD","LU2133065610.SGD","LU0787776722.HKD","LU0965509101.SGD","LU0385154629.USD","IE00BFSS7M15.SGD","CURE","LU1037948897.HKD","LU2125909593.SGD","BK7508","IE000SO60NU8.SGD","LU0726765562.USD","JNJ","LU0511384066.AUD","LU1066051811.HKD","LU1196500208.SGD","LU1366192091.USD","LU2602419157.SGD","LU0320765992.SGD","LU2237443382.USD","LU2087625088.SGD","SGXZ51526630.SGD","LU0882574139.USD","LU1267930573.SGD","IE0002141913.USD","LLII","SG9999014559.SGD","LU2112291526.USD","LU0545039389.USD","LU0823416689.USD","LU2023250843.SGD","SG9999018865.SGD","LU1244550577.SGD","OZEM","LU2756315318.SGD","LU2129689514.USD","LU1066051225.USD","LU1551013425.SGD","LU1069344957.HKD","LU2237443895.HKD","LU2023250504.SGD","LU2456880835.USD","FHLC","LU0466842654.USD","LU0426417589.USD","LU0980610538.SGD","LU1934455863.HKD","BK4516","IE00BJJMRZ35.SGD","LU0211331839.USD","LU2089283258.USD","LU1551013342.USD","LU2746668461.USD","LU2236285917.USD","IE00B3PB1722.GBP","LU1228905540.USD","LU1093756325.SGD","IE00BJJMRX11.SGD","LU0109391861.USD","LU0321505868.SGD","LU2471134796.USD","LU2592432038.USD","LU0256863902.USD","SG9999014914.USD","LU1585245621.USD","LU1934455277.USD","LU0124676726.USD","LU0456855351.SGD","LU0912757837.SGD","CANC","LU1989772923.USD","SG9999013999.USD","IE000WAW04H5.SGD","BK7511","LU0106261372.USD","LU1941712348.USD","TBXU","LU2242652126.USD","LU1506573853.SGD","LU0265550946.USD","SGXZ80539844.SGD","PBE","LU0029864427.USD","IE00B7KXQ091.USD","NVOX","LU2125154935.USD","LU1804176565.USD","GDOC","LU1941712264.USD","LU0130517989.USD","LU0128525929.USD","LU2347655156.SGD","LU2505996681.GBP","LU0267386448.USD","LU2023251221.USD","LU1162221912.USD","BK4559","LU1061106388.HKD","SG9999011175.SGD","IE00B19Z9Z06.USD","LU0094547139.USD","LU1035775433.USD","LU1496350171.SGD","LU0289739699.SGD","LU1720051017.SGD","LU0994945656.USD","LU2271345857.HKD","LU0708994859.HKD","LU1430594728.SGD","LU0122379950.USD","AGNG","LU1883839398.USD","PPH","MRK","LU2471134952.CNY","HRTS","SG9999015358.SGD","LU0861579265.USD","LU0689472784.USD","LU0985320562.USD","LU0965509010.AUD","LU1894683264.USD","LU0203345920.USD","LU1732799900.SGD","LU2237443622.USD","IE0004445239.USD","SG9999003800.SGD","LU1093756168.USD","LU2468319806.SGD","BMED","BK4534","LU0345770308.USD","LU1037948541.HKD","LU0965508806.USD","MEDX","LU0889566641.SGD","LU0345770993.USD","LU2361044949.HKD","LU2361045086.USD","LU0306806265.USD","LU2552382058.USD","LU0225771236.USD","BMY","LU0889565916.HKD","LU0154236417.USD","LU1934455194.USD","LU2491050071.SGD","LU0545562505.USD","LU0070217475.USD","LU0868494617.USD","IE0009355771.USD","LU1032955483.USD","LU0069063385.USD","BK4139","BK4588","LU0471298777.SGD","IE0002270589.USD","LU1267930813.SGD","LU2213496289.HKD","LU0130102774.USD","PFE","LU1043141396.HKD","LU1670710661.SGD","LU1983299246.USD","BK4550","BK4566","BK4599","LU1066053197.SGD","LU2168564065.EUR","SGXZ57979304.SGD","XLV","LU0882574055.USD","IE00BSNM7G36.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658535936","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑 跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2658535936","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658535936?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363243,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836820982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836820982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TRUH","APXH","BME","JDOC","FXH","BK4590","BBH","PJP","PBPH","RSPH","IYH","MEDI","IHE","BK4144","FHLC","GLP","GSKH","BBP","PPH","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641919","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641919","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:49","pubTimestamp":1786110543,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835488463.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835488463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4590","RSPH","JDOC","BBP","APXH","FXH","BK4144","FHLC","GLP","IYH","MEDI","BBH","PPH","PJP","PBPH","GSKH","TRUH","TMED","IHE","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656080539","title":"阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656080539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656080539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:26","pubTimestamp":1785835565,"startTime":"0","endTime":"0","summary":"蓝鲸新闻记者联系了阿斯利康方面，对方拒绝对此置评。此外，BMS有神经管线与Eliquis后续心血管资产，可补足AZ在相关领域的短板。据BMO资本在研报中指出，两家公司都没有足够的财务实力直接收购对方，预计阿斯利康能掏出约370亿美元，而百时美施贵宝约为320亿美元，远低于搞定一桩价值4000亿美元合并所需的资金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785835141389493693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BME","IE00BJJMRZ35.SGD","LU2596442595.SGD","LU2237443895.HKD","LU1868836591.USD","LU1093756325.SGD","LU1670710588.SGD","IE00B2B36J28.USD","LU1093756168.USD","LU2237443382.USD","IHE","FTXH","FHLC","BBH","LU0882574055.USD","LU1032466523.USD","LU0321505439.SGD","AZNH","RSPH","LU0321505868.SGD","BMY","JDOC","LU2089984988.USD","LU0868494617.USD","LU1585245621.USD","FXH","LU0225284248.USD","LU0267386448.USD","LU2242646821.SGD","LU0985481810.HKD","PPH","LU1868837300.USD","AZN","LU2462157665.USD","LU1670711123.USD","LU0128525929.USD","MEDI","LU1868836914.USD","LU0432979614.USD","BBP","AZ","IYH","BK4588","APXH","GSKH","PBPH","PJP","TRUH","BK4559","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656493343","title":"據英國金融時報報道英國製藥商阿斯利康一直在探索與美國競爭對手百時美施貴寶合併的交易合併後將打造全球最大的製藥集團之一市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2656493343","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656493343?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 03:22","pubTimestamp":1785698576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0289739699.SGD","FTXH","IHE","LU1261432733.SGD","GSKH","LU0889565916.HKD","AZN","LU1093756168.USD","LU1267930573.SGD","LU1868836757.USD","LU2417539215.USD","LU2125154778.USD","LU1989771016.USD","AZNH","LU0456855351.SGD","LU0708994859.HKD","LU0061475181.USD","BK4534","BK4007","LU0321505868.SGD","LU1868837300.USD","LU2236285917.USD","LU2237443895.HKD","BK4532","LU1868837136.USD","LU2237443978.SGD","LU0306806265.USD","LU0868494617.USD","BK4588","IE00B2B36J28.USD","LU0114720955.EUR","IE0009355771.USD","LU2360032135.SGD","LU2456880835.USD","LU1670711123.USD","LU2125154935.USD","LU2237443549.SGD","LU2089984988.USD","LU1571399168.USD","BMY","LU0225771236.USD","IE00BJJMRZ35.SGD","LU2133065610.SGD","IE00B3T34201.USD","LU1323610961.USD","LU0321505439.SGD","LU0109394709.USD","BK4559","LU1032466523.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655336136","title":"GSK上半年核心營業利潤增長 管線優化同步推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2655336136","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655336136?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502815,"startTime":"0","endTime":"0","summary":"7月28日，葛兰素史克（GSK）公布2026年第二季度及上半年业绩。财报显示，今年上半年，葛兰素史克实现总营收160.38亿英镑，同比增长5%（以固定汇率计价，下同）；受期内药物临床试验失败等因素影响，公司总营业利润为27.74亿英镑，同比减少31%。不过，公司核心营业利润（剔除非经常性项目后的“常态化”利润）为54.50亿英镑，同比增长8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828578150.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828578150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","BK4588","BK4585","GSK","BK4007","BK4532","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654888584","title":"美股異動 | 醫藥板塊走強 葛蘭素史克(GSK.US)績後大升逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654888584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654888584?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 22:50","pubTimestamp":1785250222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4588","LU1829250122.USD","GSK.UK","GSKH","BK4007","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117275596","title":"美股異動｜醫藥股板塊普漲，葛蘭素史克漲近7%，安進升逾5%，艾伯維公司漲近4%，輝瑞、默沙東升逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117275596","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117275596?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 22:29","pubTimestamp":1785248946,"startTime":"0","endTime":"0","summary":"7月28日，医药股板块普涨，葛兰素史克涨近7%，安进涨超5%，艾伯维公司涨近4%，辉瑞、默沙东涨超3%，强生涨近3%，礼来涨超2%。消息面上，葛兰素史克公布的二季度财报显示，调整后每股收益为50.5便士，显著高于市场预期的46.8便士，盈利表现超出预期。与此同时，葛兰素史克宣布计划到2029年全面实现每年19亿英镑的成本节约，这一目标进一步增强了投资者对公司未来盈利能力的信心。","market":"us","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIL","AMGN","LLY","GSK","PFE","JNJ","ELIS","MRK","LLYX","LLII","LLYZ","GSKH","ABBV"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1134607161","title":"美股開盤 | 三大指數升跌不一，康寧跌超14%，葛蘭素史克升逾4%，可口可樂升逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134607161","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134607161?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 21:31","pubTimestamp":1785245499,"startTime":"0","endTime":"0","summary":"7月28日，美股三大指数开盘涨跌不一，道指涨0.66%，纳指跌0.61%，标普500跌0.14%。康宁跌超14%，Q2营收利润双超预期，但Q3收入指引不够“惊喜”；葛兰素史克涨超4%，可口可乐涨超3%，波音、PayPal涨近1%。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH",".IXIC","SPUU","BK4170","SDS","IVV","LU2290526834.HKD","LU2360107168.USD","SSO","SMAX","SPDN","SPYH","LU0054578231.USD","SPXU","SPYM","DDM","SPYU","SH","UDOW","DRAM","GLW","LU1861220033.SGD","SPXS","BOEU","RAM","MMAX","DIA","BOEG","PYPG","CNAV","HIBL","UPRO",".DJI","GSK","UDN","BOED","SPYQ","VOO","SPY","GLWG","LU1861215975.USD","SPXL","DOG","LU0963586101.USD","DXD","UUP","BK4588","PYPL","DMAX","SDOW","KO","YSPY",".SPX","PTF","PYPY","BA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001756","title":"葛蘭素史克首席執行官：媒體電話會議發言稱，我們認為公司現有營收與收益流規模充足，足以抵消艾滋病藥物專利失效帶來的損失。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001756","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001756?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:03","pubTimestamp":1785240196,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSKH","LU1829250122.USD","GSK.UK","BK4532","BK4007","BK4588","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016400","title":"葛蘭素史克首席執行官就劍橋投資表示，我們並未尋求英國政府支持。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016400?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:52","pubTimestamp":1785239557,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","GSK.UK","BK4007","GSK","GSKH","LU1829250122.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":90,"code":"91000000","status":"200"}]}}